Journal
FUTURE ONCOLOGY
Volume 12, Issue 4, Pages 477-491Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.342
Keywords
Bruton's tyrosine kinase; ibrutinib; mantle cell lymphoma
Categories
Funding
- Janssen-Cilag Ltd.
Ask authors/readers for more resources
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL. Although the majority of disease responses are partial, efficacy data are impressive with more than two-thirds of patients demonstrating a durable response. This article focuses on all aspects of ibrutinib in the context of MCL, including a summary of the basic pharmacology and pharmacokinetics; a review of the safety and efficacy data published to date and a discussion of the future implications in MCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available